Steensma et al. enrolled 502 patients with non-myeloid malignancies undergoing chemotherapy with Hb < 110 g/L to receive either IV FG every 3 weeks, oral iron, or oral placebo at a 1:1:1 ratio for 16 weeks [48]. This evidence concerns the gene GSTM1 and myeloid neoplasm.